MeiraGTx Holdings plc MGTX R2KR3KPHARMA
Company Overview
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Why Investors Should Care
Generates a return on equity of 72.2%, reflecting efficient use of shareholder capital.
Revenue has grown at a 35.3% CAGR over the past five years.
Trades at a P/E of 10.6, below the sector median of 25.4.
Maintains a net profit margin of 19.9%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $81.39M (+144.6% YoY); net profit $-114.20M.
- 5-Year Trend Long-term compounding — revenue CAGR 35.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 35.26% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +10.43% |
| 6 Months: | -0.22% |
| 3 Months: | -25.12% |
| 1 Month: | -16.65% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)32.19 · Neutral
P/E of 10.59 is below the sector median of 25.45 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 72.2%.
- Compounding revenue at 35.3% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 38.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MGTX MeiraGTx Holdings plc R2KR3KPHARMA | 9.21 | 10.59 | $884.56M | 0.00% | -86.95% | 72.17% | 35.26% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 784.96K | 1.98M | 3.58M | 4.21M | 2.47M | 5.09M | 4.59M | 5.12M | 6.95M | 5.63M | 10.76M | 4.82M | 3.33M | 3.54M | 5.10M | - | - | - | - | - | - | - |
| Operating Income | -7.59M | -8.76M | -18.05M | -25.17M | -14.74M | -20.69M | -21.23M | -10.91M | -15.68M | -25.23M | -8.43M | -22.03M | -20.48M | -22.55M | -28.73M | -23.76M | -22.81M | -31.76M | -28.79M | -32.76M | -46.77M | -45.91M | -40.04M | -41.60M | -44.79M | -46.05M | -40.82M |
| Net Income | -7.18M | -8.44M | -16.40M | -29.98M | -15.42M | -17.98M | -20.82M | -10.46M | -15.68M | -25.42M | -6.43M | -23.62M | -20.09M | -25.95M | -31.05M | -33.97M | -37.28M | -30.36M | -29.58M | -44.30M | -20.44M | -48.62M | -39.33M | -39.98M | -38.80M | -50.51M | -46.31M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.17 | -0.54 | -0.46 | -0.59 | -0.70 | -0.76 | -0.83 | -0.62 | -0.53 | -0.74 | -0.32 | -0.76 | -0.55 | -0.51 | -0.48 | -0.62 | -0.57 |
| R&D Expense | 5.36M | 6.39M | 6.93M | 7.79M | 8.11M | 12.98M | 9.77M | 4.61M | 8.08M | 16.20M | 4.63M | 16.71M | 15.19M | 21.61M | 23.10M | 24.00M | 16.86M | 22.32M | 19.94M | 27.86M | 34.32M | 34.93M | 26.24M | 32.78M | 33.49M | 32.53M | 31.98M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 13.29M | 15.56M | 37.70M | 15.92M | 14.02M | 33.28M | 81.39M |
| Operating Income | -31.68M | -78.10M | -58.27M | -62.55M | -72.76M | -116.36M | -137.06M | -164.21M | -105.97M |
| Net Income | -31.04M | -82.87M | -54.75M | -57.99M | -79.56M | -129.62M | -84.03M | -147.79M | -114.20M |
| Diluted EPS | - | - | - | -1.54 | -1.80 | -2.87 | -1.49 | -2.12 | -1.42 |
| R&D Expense | 22.36M | 33.62M | 24.88M | 33.91M | 66.69M | 85.72M | 103.78M | 119.48M | 129.62M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 25.85M | 96.89M | 323.89M | 363.70M | 320.16M | 318.24M | 326.74M | 269.75M | 244.43M |
| Total Equity | -17.14M | -47.37M | 81.06M | 190.80M | 238.56M | 185.40M | 117.74M | 138.18M | 67.83M | -5.79M |
| Cash & Equivalents | - | 8.55M | 68.08M | 227.23M | 209.52M | 137.70M | 115.52M | 129.57M | 103.66M | 65.93M |
| Total Liabilities | - | 21.88M | 15.84M | 133.09M | 125.14M | 134.76M | 200.50M | 188.57M | 201.92M | 250.22M |
| Current Liabilities | - | 21.40M | 15.50M | 49.20M | 54.15M | 68.13M | 82.07M | 67.08M | 60.78M | 122.56M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -18.06M | -58.89M | 20.04M | -63.97M | - | -73.10M | -105.36M | -104.50M | -46.36M |
| Investing Cash Flow | -10.54M | -11.26M | -9.37M | -37.02M | - | -44.96M | 34.03M | 23.48M | -4.11M |
| Financing Cash Flow | 19.34M | 130.04M | 148.23M | 82.73M | - | 95.20M | 84.02M | 54.53M | 12.27M |
| Capital Expenditure | -10.54M | -11.26M | -8.98M | -20.92M | - | -44.96M | -20.17M | -4.96M | -4.24M |
| Free Cash Flow | -28.59M | -70.15M | 11.06M | -84.89M | - | -118.06M | -125.54M | -109.45M | -50.59M |
| Net Change in Cash | - | - | - | - | - | -22.86M | 12.69M | -26.48M | -38.19M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -438.4% | -401.9% | -193.0% | -730.9% | -977.8% | -493.4% | -130.2% |
| Net Margin % | - | - | -411.9% | -372.6% | -211.0% | -814.2% | -599.5% | -444.1% | -140.3% |
| ROE % | 65.5% | -102.2% | -28.7% | -24.3% | -42.9% | -110.1% | -60.8% | -217.9% | 1,971.4% |
| ROCE % | -711.6% | -96.0% | -21.2% | -20.2% | -28.9% | -49.3% | -52.8% | -78.6% | -86.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Sanofi | 12.70% | 12.20M | $130.39M |
| 2 | Perceptive Advisors Llc | 11.23% | 10.79M | $115.31M |
| 3 | Rubric Capital Management LP | 9.47% | 9.10M | $97.28M |
| 4 | Johnson & Johnson | 6.91% | 6.64M | $70.99M |
| 5 | Blackrock Inc. | 4.95% | 4.76M | $50.85M |
| 6 | Adage Capital Partners GP L.L.C. | 4.58% | 4.40M | $47.04M |
| 7 | Opaleye Management Inc. | 3.70% | 3.55M | $37.95M |
| 8 | Millennium Management Llc | 3.09% | 2.97M | $31.77M |
| 9 | 683 Capital Management LLC | 2.39% | 2.30M | $24.59M |
| 10 | Woodline Partners LP | 1.56% | 1.50M | $16.04M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MGTX
MeiraGTx Holdings plc Estimates – NASDAQ:MGTX - TradingView
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE8zbjJDRFJTTTlOUUVGYWZYVzdsdzZ2d3Zrc2U0dVAtc3EzcTk1V0plVElCclQwWGdiOGgxQjl3SHNxcjF1TzlKYVlZZ1VBa01MRkxGNGVhUVlVOVBqZ0h3eG54c1pYczBLWUxqbHRrN2FrN2FtOEFCVw?oc=5" target="_blank">Meira…
Can MeiraGTx Holdings PLC (MGTX) Stock Double? Cash Runway Offers a Hint - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPdlJPM0Fqc0k1dklGcUlzNE9OYkpzNzhlTkgwd3lLdmY4OUEzazBSZXU2S3RIYzE1OHJmcXhEendhVGxURlJ6OFloR1RtMm0tQVFCZGh2TnBaMHdHRkVrVDBUTGRsSm1wTUswQUZHcFBsU3ByNXc4bGtpR0ZRRi1QeWtkVWc3U0x6a25SU0…
MeiraGTx CFO & COO Richard Giroux sells $557,200 in company shares - Investing.com Nigeria
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNc1o1MTBmNWROZ1N0dXktSmpTSDBWenlHeTBLSmNUYnBpcFhKaU1PWWcxdjlMZ2pNOVdhLU5DbGVtQVJMdUYzRjA3RFlYYklSS2VYYlJfMHByUV8yS2lwbmF6QTFsSVhROFZ5YTJ2N1FEd3FJQXFkdWNsQU5ROHpJd0I1UGR5QzR6TFRsZG…
A $557K share sale is proposed by MeiraGTx (MGTX) officer Richard Giroux. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNc0NKR1EzbEluUHJjTUpBR2JxVDBQZTlFU3ljRGI3b0lKQk5EUE5ra3lnX3l5SmdoLWhOckZ6aEd1Q1MyelluOHUtOS1oMjF4RHIwSGhqdG9xdG1aZkxkMkxRbFlKNEhMeGdvRGcwNzh4SkkwZTBJQTcxaW1sZ20wRjhQTHBzSFNZREpuVk…
Strength Seen in MeiraGTx (MGTX): Can Its 6.2% Jump Turn into More Strength? - qz.com
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxPRDFYbUdYWkJGYVdWZjExcjRhQmtQNHV4WmFSbmE0dGlVaWtxNkpqSWJuNThMOTNQUVp0dzE2UGNycjczOXNmMEFPYzluU2lodFN4NjNoMmllWmozQW9tcHZGYWh6cmtFb0NudzBiM0ZLQzVRZEVRcXhKY2RZYkZDYXJmNWhCX2RIR3RGd0…
MGTX Nov 2026 7.500 call (MGTX261120C00007500) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTFBOT2N5OTRvMWxIS1pGYk0yQ2VCSnc3Y1phbHlsT0R6dHlUTmoxYjRuUHpKbjZUdjJMcWNvMEFZSEJCOEJyRElSYTNqVFprcDRQZ2cwU3hVQmNZcWwxdkNNYnZWV0NOdw?oc=5" target="_blank">MGTX Nov 2026 7.500 call (MGT…
MGTX — Frequently Asked Questions
What is the current share price of MeiraGTx Holdings plc (MGTX)?
As of 2026-10-23 16:27 PDT, MeiraGTx Holdings plc (MGTX) trades at $9.21 on NasdaqGS. Its 52-week range is $6.99 to $14.97.
What is the market capitalisation of MGTX?
MeiraGTx Holdings plc (MGTX) has a market capitalisation of $884.56M on NasdaqGS.
What is the P/E ratio of MGTX?
MGTX trades at a trailing price-to-earnings (P/E) ratio of 10.59. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 5.79.
What is the return on equity (ROE) of MGTX?
MGTX has a return on equity (ROE) of 72.17%. Its return on capital employed (ROCE) is -86.95%.
Is MGTX a good stock to buy?
This page provides a data-driven analysis of MeiraGTx Holdings plc (MGTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.